Iconovo strengthens patent protection for ICOres® in the EU

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the European Patent Office (EPO) intends to approve Iconovo's application for yet another patent for the inhalation platform ICOres®. ICOres® is already being used in several of Iconovo's customer projects, and this new patent strengthens the intellectual property rights, benefiting customers who will launch pharmaceutical products based on the company's unique inhaler in the future.

Iconovo receives additional development contract from Kiox Pharma for new inhalable treatment against rare disease

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has entered into an agreement to conduct a preclinical pharmacokinetic study with Danish rare lung disease company Kiox Pharma. This is a continuation of the collaboration between the companies that was announced in a press release on June 9th this year. The new agreement entails revenues of SEK 1.1 million for Iconovo, in addition to the SEK 0.5 million that the company has already received.

Iconovo får ytterligare utvecklingsuppdrag av Kiox Pharma gällande ny inhalerbar behandling mot sällsynt sjukdom

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar idag att företaget ingått ett avtal om genomförande av en preklinisk farmakokinetisk studie med danska Kiox Pharma, verksamma inom sällsynta lungsjukdomar. Detta innebär en fortsättning av det samarbete mellan bolagen som annonserades i ett pressmeddelande den 9 juni i år. Det nya avtalet innebär intäkter om 1,1 miljoner kronor till Iconovo, i tillägg till de 0,5 miljoner kronor som bolaget redan har erhållit.

Iconovo confirms its long-term financial targets for 2027 with expected full-year profitability in 2026

Iconovo AB (publ), which develops complete inhalation products for a global market, announces today that the company expects to achieve profitability in a single quarter in both 2024 and 2025 and full-year profitability from 2026. For 2027, revenues of SEK 250 million are expected with an EBITDA margin of 50 percent, which is in line with the financial targets communicated in June 2022. Approximately 85 percent of the projected revenues come from projects that have already been initiated. The company's strategic focus on its offering in contract development (CDMO) of inhalable drugs is an important contributing factor and the target for the number of new deals is raised to three to five new agreements per year.

Iconovo befäster sina långsiktiga finansiella mål för 2027, förväntad helårslönsamhet 2026

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar idag att bolaget räknar med att uppnå lönsamhet under ett enskilt kvartal såväl 2024 som 2025 och helårslönsamhet från och med 2026. För år 2027 förväntas intäkter om 250 miljoner kronor med en EBITDA-marginal på 50 procent, vilket är i linje med de mål som kommunicerades i juni 2022. Cirka 85 procent av de prognosticerade intäkterna kommer från projekt som redan har initierats. Bolagets strategiska satsning på sitt erbjudande inom kontraktsutveckling (CDMO) av inhalerbara läkemedel är en viktig bidragande faktor och målet för antal nya affärer höjs till tre till fem nya avtal per år.

Iconovo ökar försäljningsinsatserna och säkrar produktionen för ICOcap genom omstrukturerat avtal med Stevanato

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar att man har återtagit de globala rättigheterna att sälja och distribuera ICOcap® inhalatorer från Stevanato Group. Iconovo avser nu att kraftigt öka försäljningsinsatserna avseende ICOcap® medan Stevanato Group kommer att förbli enda kontraktstillverkare av ICOcap. I samband med omstruktureringen av avtalet kommer Iconovo att erhålla en betalning om EUR 200 000 under tredje kvartalet som ska användas för att ansöka om CE-märkning av ICOcap. Den förändrade samarbetsstrukturen förväntas öka bolagets framtida vinstmarginal på sålda produkter.

Iconovo increases sales efforts and supply chain security for ICOcap through restructured agreement with Stevanato

Iconovo AB (publ), which develops complete inhalation products for a global market, announces that it has regained the global rights to sell and distribute ICOcap® inhalers from Stevanato Group. Iconovo now aims to increase sales efforts pertaining to ICOcap®, and Stevanato Group will serve as the sole manufacturing partner. In conjunction with restructuring the agreement, Iconovo will receive a payment of EUR 200,000 during the third quarter to be used for the application for CE certification of ICOcap. The amended collaboration structure is expected to increase the company's future profit margin on products sold.

Iconovo inleder feasibility-studie med Affilogic för utveckling av inhalerbara Nanofitin®-baserade bioterapier

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar idag att man har ingått ett samarbetsavtal med det franska bioteknikföretagetAffilogic avseende genomförandet av en feasibility-studie av inhalerbara affinitetsproteiner, Nanofitins®, baserat på Iconovos inhalatorplattform ICOone® . Projektet syftar till att utveckla en ny behandling för lungsjukdomar.

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that it has entered into a feasibility agreement with Affilogic, a French biotech company, regarding the implementation of a feasibility study of inhalable affinity proteins Nanofitins® in Iconovo's ICOone. The project aims to develop a new treatment for lung diseases.

Iconovo initiates collaboration with a small Danish company to develop a new inhalable treatment for a rare disease

Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that it has entered an agreement with a small Danish development company to conduct a feasibility study with a reformulated inhalable version of an already approved drug substance in one of Iconovo's patented inhalers. The project aims to develop a new treatment for a rare disease and gives Iconovo an initial revenue of SEK 0.5 million. Thereafter, a possible license agreement may generate additional revenue through contract services, milestone and royalty payments, or sales of inhalers. Concurrently, another of the new customer's pharmaceutical projects is being evaluated for possible inclusion in the Iconovo Accelerator Program – a newly established initiative to facilitate opportunities for obtaining EU funding. The current agreement pertains to an initial three-month feasibility study of an inhalable version of an already market-approved drug. The aim is to use one of Iconovo's patented inhalers to develop a new treatment for a rare inflammatory disease that usually affects the lungs. Assuming a positive outcome of the feasibility study, the development company intends to apply for orphan drug status through an orphan drug designation request to the US Food and Drug Administration (FDA). Orphan drug status allows for profitable sales of drugs for rare diseases despite small volumes. Iconovo assesses that the new treatment has a high market potential.